Literature DB >> 11494090

A physician-pharmacist model for the surveillance of blood pressure in the community: a feasibility study.

K A Earle1, P Taylor, S Wyatt, S Burnett, J Ray.   

Abstract

Hypertension is poorly managed. Hospital-based pharmacists working with physicians have been shown to improve the rate of achievement of "target" blood pressure in selected patients. It is unknown if such schemes can operate in the community and to what extent they would attract volunteers with poorly managed blood pressure. We assessed the feasibility of pharmacists to provide community-based, open-access, blood pressure monitoring. In addition, we describe the blood pressure profile of the group in comparison to that of the 1994 Health Survey of England (HSE). Pharmacists from six pharmacies were trained to deliver the service. Adults living within the postal districts of the pharmacies were invited, through an advertising campaign, to volunteer to have their blood pressure measured. Blood pressure data and information on treatment for hypertension and/or diabetes were collected on 263 registrants. Patients were advised to have their blood pressure managed by the general practitioner immediately (category 1), re-measured within 2-3 months (category 2) or in 12 months time (category 3). The mean (s.d.) blood pressure of patients in categories 1 (n = 16), 2 (n = 117) and 3 (n = 130) was 186(16)/97(29), 151(13)/94(9) and 139(22)/86(13) mm Hg respectively; P < 0.001. Ninety-one patients (35%) were in receipt of antihypertensive therapy. Forty-five percent of the treated group had controlled blood pressure (<160/95 mm Hg) compared with 30% in the HSE dataset. A large proportion of known hypertensive patients with poor blood pressure control who had visited their general practitioner within the previous 6 months were detected by the pharmacist-led service. Pharmacists operating an open-access blood pressure monitoring service may be of value in improving the management of hypertension.

Entities:  

Mesh:

Year:  2001        PMID: 11494090     DOI: 10.1038/sj.jhh.1001220

Source DB:  PubMed          Journal:  J Hum Hypertens        ISSN: 0950-9240            Impact factor:   3.012


  7 in total

Review 1.  Role of community programs in controlling blood pressure.

Authors:  Robinson Fulwood; Jeanette Guyton-Krishnan; Madeleine Wallace; Ellen Sommer
Journal:  Curr Hypertens Rep       Date:  2006-12       Impact factor: 5.369

2.  Views of the Scottish general public on community pharmacy weight management services: international implications.

Authors:  Anita Elaine Weidmann; Scott Cunningham; Gwen Gray; Denise Hansford; Giovanna Bermano; Derek Stewart
Journal:  Int J Clin Pharm       Date:  2012-03-02

3.  Accuracy of monitors used for blood pressure checks in English retail pharmacies: a cross-sectional observational study.

Authors:  James Hodgkinson; Constantinos Koshiaris; Una Martin; Jonathan Mant; Carl Heneghan; Fd Richard Hobbs; Richard J McManus
Journal:  Br J Gen Pract       Date:  2016-03-29       Impact factor: 5.386

Review 4.  Medication review and reconciliation with cooperation between pharmacist and general practitioner and the benefit for the patient: a systematic review.

Authors:  Marlies M E Geurts; Jaap Talsma; Jacobus R B J Brouwers; Johan J de Gier
Journal:  Br J Clin Pharmacol       Date:  2012-07       Impact factor: 4.335

5.  Evaluation of PROforma as a language for implementing medical guidelines in a practical context.

Authors:  David R Sutton; Paul Taylor; Kenneth Earle
Journal:  BMC Med Inform Decis Mak       Date:  2006-04-05       Impact factor: 2.796

6.  Experiences of the Pharmacy-Led Weight Management Service: Views of Service Providers in England.

Authors:  Aliki Peletidi; Reem Kayyali
Journal:  Pharmacy (Basel)       Date:  2019-07-03

7.  The effectiveness of screening for diabetes and cardiovascular disease risk factors in a community pharmacy setting.

Authors:  Andrew Willis; Peter Rivers; Laura J Gray; Melanie Davies; Kamlesh Khunti
Journal:  PLoS One       Date:  2014-04-01       Impact factor: 3.240

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.